Merck, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: $295.3B

Website: http://www.merck.ph

Clinical Trials

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension

Phase 3

Completed

Conditions: Gastroesophageal Junction Cancer
Gastric Cancer

Interventions: Biological: Pembrolizumab
Drug: Placebo
Drug: Cisplatin
Drug: Capecitabine
Drug: Docetaxel
Drug: 5-fluorouracil
Drug: Oxaliplatin
Drug: Leucovorin

First Posted Date: 2021-05-11

Last Posted Date: 2025-05-28

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 120

Registration Number: NCT04882241

Locations: 🇨🇳
Afflilated Hospital of Bengbu Medical College-Surgical Oncology (Site 0638), Bengbu, Anhui, China
🇨🇳
Tangdu Hospital of Fourth Military Medical University of Chinese People's Liberation Army ( Site 0647), Xi'an, Shaanxi, China
🇨🇳
Beijing Friendship Hospital ( Site 0637), Beijing, Beijing, China

and more 17 locations

A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68)

Phase 2

Active, not recruiting

Conditions: Hodgkin's Lymphoma
Primary Mediastinal Large B-cell Lymphoma (PMBCL)

Interventions: Biological: Pembrolizumab

First Posted Date: 2021-05-06

Last Posted Date: 2025-02-10

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 66

Registration Number: NCT04875195

Locations: 🇺🇸
Lundquist Institute for Biomedical Innovation at Harbor-UCLA-Hematology and Medical Oncology ( Site, Torrance, California, United States
🇨🇿
Fakultni nemocnice Brno Bohunice-Interni hematologicka a onkologicka klinika ( Site 0302), Brno, Brno-mesto, Czechia
🇨🇿
Fakultni nemocnice Kralovske Vinohrady-Interni hematologicka klinika ( Site 0303), Prague, Praha 10, Czechia

and more 24 locations

Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001) - China Extension Study

Phase 3

Completed

Conditions: Endometrial Neoplasms

Interventions: Drug: Lenvatinib
Drug: Paclitaxel
Drug: Carboplatin
Biological: Pembrolizumab

First Posted Date: 2021-04-29

Last Posted Date: 2025-02-11

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 130

Registration Number: NCT04865289

Locations: 🇨🇳
Fudan University Shanghai Cancer Center ( Site 2500), Shanghai, Shanghai, China
🇨🇳
Women s Hospital School of Medicine Zhejiang University ( Site 2511), Hangzhou, Zhejiang, China
🇨🇳
Anhui Cancer Hospital-Gynecological Oncology ( Site 2509), Hefei, Anhui, China

and more 19 locations

Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)-China Extension

Phase 3

Withdrawn

Conditions: Stomach Neoplasms

Interventions: Biological: Pembrolizumab
Drug: Cisplatin
Drug: 5-fluorouracil
Drug: Oxaliplatin
Drug: Placebo for Pembrolizumab
Drug: Capecitabine

First Posted Date: 2021-04-26

Last Posted Date: 2021-12-16

Lead Sponsor: Merck Sharp & Dohme LLC

Registration Number: NCT04859582

Locations: 🇨🇳
Peking Union Medical College Hospital ( Site 2425), Beijing, Beijing, China
🇨🇳
Fujian Medical University Union Hospital ( Site 2410), Fuzhou, Fujian, China
🇨🇳
900 Hospital of the Joint ( Site 2418), Fuzhou, Fujian, China

and more 25 locations

A Study of Belzutifan (MK-6482) in Participants With Advanced Clear Cell Renal Cell Carcinoma (MK-6482-018)

Phase 1

Active, not recruiting

Conditions: Carcinoma, Renal Cell

Interventions: Drug: Belzutifan

First Posted Date: 2021-04-15

Last Posted Date: 2024-11-22

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 52

Registration Number: NCT04846920

Locations: 🇺🇸
University of Michigan ( Site 1006), Ann Arbor, Michigan, United States
🇺🇸
Beth Israel Deaconess Medical Center ( Site 1002), Boston, Massachusetts, United States
🇺🇸
Vanderbilt University Medical Center-Vanderbilt-Ingram Cancer Center ( Site 1005), Nashville, Tennessee, United States

and more 1 locations

Open-label, Follow-up of Doravirine/Islatravir (DOR/ISL 100 mg/0.75mg) for Participants With Human Immunodeficiency Virus-1 (HIV-1) Infection (MK-8591A-033)

Phase 3

Active, not recruiting

Conditions: HIV-1 Infection

Interventions: Drug: MK-8591A

First Posted Date: 2021-03-01

Last Posted Date: 2024-11-15

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 2000

Registration Number: NCT04776252

Locations: 🇺🇸
One Community Health ( Site 0045), Sacramento, California, United States
🇺🇸
Whitman-Walker Institute ( Site 0039), Washington, District of Columbia, United States
🇺🇸
Georgetown University Medical Center-Clinical Trials Unit Division of Infectious Diseases ( Site 002, Washington, District of Columbia, United States

and more 90 locations

Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017)

Phase 3

Completed

Conditions: Colorectal Neoplasms

Interventions: Drug: pembrolizumab
Drug: regorafenib
Drug: TAS-102 (trifluridine and tipiracil)
Drug: lenvatinib

First Posted Date: 2021-03-01

Last Posted Date: 2024-10-29

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 480

Registration Number: NCT04776148

Locations: 🇨🇦
NSHA-QEII Health Sciences Centre-Dickson Bldg-Dept. of Medical Oncology ( Site 0200), Halifax, Nova Scotia, Canada
🇯🇵
Shizuoka Cancer Center ( Site 1706), Nagaizumi, Shizuoka, Japan
🇩🇰
Herlev and Gentofte Hospital-Department of Oncology ( Site 0704), Copenhagen, Hovedstaden, Denmark

and more 92 locations

Immunogenicity and Safety of the 9-valent Human Papillomavirus (9vHPV) Vaccine in Japanese Boys and Girls (V503-066)

Phase 3

Completed

Conditions: Papillomavirus Infections

Interventions: Biological: 9vHPV vaccine

First Posted Date: 2021-02-26

Last Posted Date: 2025-05-30

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 314

Registration Number: NCT04772534

Locations: 🇯🇵
Motomachi Pediatric Clinic ( Site 6606), Sapporo, Hokkaido, Japan
🇯🇵
Ohigesenseino Kodomo Clinic ( Site 6607), Sapporo, Hokkaido, Japan
🇯🇵
Fukui General Hospital ( Site 6614), Fukui, Japan

and more 9 locations

Efficacy and Safety of Clesrovimab (MK-1654) in Infants (MK-1654-004)

Phase 2

Completed

Conditions: Respiratory Syncytial Virus Infection

Interventions: Drug: Placebo
Biological: Clesrovimab

First Posted Date: 2021-02-23

Last Posted Date: 2025-05-06

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 3632

Registration Number: NCT04767373

Locations: 🇺🇸
Children's Clinic of Jonesboro, PA ( Site 0058), Jonesboro, Arkansas, United States
🇺🇸
Senders Pediatrics ( Site 0062), Cleveland, Ohio, United States
🇺🇸
UPMC Children's Hospital of Pittsburgh - Primary Care Center - Oakland ( Site 0043), Pittsburgh, Pennsylvania, United States

and more 214 locations

Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004)

Phase 2

Active, not recruiting

Conditions: Advanced Hepatocellular Carcinoma

Interventions: Biological: Pembrolizumab/Quavonlimab
Drug: Lenvatinib
Biological: Pembrolizumab

First Posted Date: 2021-02-05

Last Posted Date: 2023-11-13

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 110

Registration Number: NCT04740307

Locations: 🇺🇸
Johns Hopkins Hospital-Sidney Kimmel Comprehensive Cancer Center - GI and Immunology ( Site 0013), Baltimore, Maryland, United States
🇨🇭
CHUV (centre hospitalier universitaire vaudois) ( Site 0333), Lausanne, Vaud, Switzerland
🇪🇸
Hospital Universitario Central de Asturias-Hepatology ( Site 0309), Oviedo, Asturias, Spain

and more 37 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy